Polyphor AG, Kolummne

Polyphor AG: Outer-Membrane Protein Targeting Antibiotics - New hope against antibiotic resistance

24.04.2017 - 18:17:24

Polyphor AG: Outer-Membrane Protein Targeting Antibiotics - New hope against antibiotic resistance. Polyphor AG: Outer-Membrane Protein Targeting Antibiotics (OMPTAs) - New hope against antibiotic resistance

^

EQS Group-News: Polyphor AG / Schlagwort(e): Studie

Polyphor AG: Outer-Membrane Protein Targeting Antibiotics (OMPTAs) - New

hope against antibiotic resistance

24.04.2017 / 18:15

Outer-Membrane Protein Targeting Antibiotics (OMPTAs) - New hope against

antibiotic resistance

- Important step forward for nosocomial pneumonia treatment -

Vienna, Austria, April 24, 2017 - Polyphor today presented promising data

for their novel class of antibiotics, the Outer Membrane Protein Targeting

Antibiotics (OMPTA). This is the first new class of antibiotic against

Gram-negative pathogens to reach advanced clinical development in over 40

years. Murepavadin (POL7080), the first member of the OMPTA class -

currently in Phase II and soon expected to enter Phase III - is being

developed for the treatment of the most severe Pseudomonas aeruginosa (PA)

infection - nosocomial pneumonia (including hospital-acquired and

ventilator-associated pneumonia) - a disease with a death rate of 20-50%.1

Early initiation of effective antimicrobial treatment for PA pulmonary

infections is critical and a strong predictor of mortality.2 However,

multi-drug resistant (MDR) PA has become a global problem and, as such,

treatment is becoming more challenging with limited options available.

Murepavadin, by means of its novel and unique mechanism of action, is

extremely active and is being developed as first line treatment for MDR

cases.

Dr Ignacio Martin-Loeches, St James' Hospital, Trinity College, Dublin

(Ireland) explained, "PA represents a significant threat to the most

vulnerable hospital patients, including intensive care patients, those with

depleted immune systems such as those with cancer, people with severe burns

and premature babies in neonatal units. Treatment options are limited and so

this new class of antibiotics is desperately needed."

Data presented today at the 27th European Congress of Clinical Microbiology

and Infectious Diseases (ECCMID) have shown a high rate of clinical cure

(91%) and low rate of mortality (9%) at day 28 in a small patient group (12

patients), when treated with Murepavadin.3 They also demonstrated that

multiple doses of Murepavadin were considered to be safe and with acceptable

tolerability.3

"Antibiotic resistance is one of the most serious health threats of our time

with significant global implications. New treatment options are urgently

needed", highlighted Prof. Antoni Torres, Respiratory Institute Hospital

Clinic, Barcelona (Spain). "Today's announcement that Murepavadin has shown

positive benefits in the trials offers hope for the management of this

challenging patient group."

Dr Glenn Dale, Head of Early Development, Antimicrobials, Polyphor added,

"Murepavadin's single pathogen focus prevents a build-up of resistance

against other pathogens, which is a common problem with antibiotics. Today's

findings show that our proposed dose of Murepavidin could be a promising new

antimicrobial to treat PA.4 This year, we expect Murepavadin to enter Phase

III trials and take another step to bring it to patients. In addition, our

OMPTA platform could bring further new important therapies in the treatment

of Gram-negative pathogens."

Contact:

Catherine Hof Jo Hewitt

Corporate Communications Director

Polyphor Ltd HAVAS Just::

Tel: +41 61 567 16 00 Tel: +44 208 877 8421

Email: [1]PR@polyphor.com Email: [1]jo@justhealthcomms.com

1. mailto:jo@justhealthcomms.com 1. mailto:jo@justhealthcomms.com

About Polyphor

Polyphor is a clinical stage, privately held Swiss specialty pharma company,

focused on the development of macrocycle drugs that address antibiotic

resistance and severe respiratory diseases. The company's lead drug

candidates include:

- Murepavadin (POL7080, in Phase II entering Phase III / Pivotal

registration program), a precision Outer Membrane Protein Targeting

Antibiotic (OMPTA) against Pseudomonas Aeruginosa.

- POL6014 (in Phase Ib), an inhaled inhibitor of neutrophil elastase for the

treatment of cystic fibrosis and other severe lung diseases.

- Balixafortide (POL6326, in Phase Ib), an antagonist of the chemokine

receptor CXCR4 for combination treatment in oncology.

Polyphor has discovered the OMPTA class and is further developing it,

including a broad-spectrum preclinical candidate, to address infections

caused by difficult-to-treat, resistant Gram-negative pathogens - one of the

most pressing emerging medical needs. The OMPTA represent the first new

class of antibiotics against Gram-negative bacteria reaching advanced

clinical stage in the last 40 years.

In addition, Polyphor has an important activity of discovery technology

partnerships to assist pharma companies in research programs addressing

difficult targets through its proprietary macrocycle technology platform.

Polyphor has several industry partnerships with and financing from the

Cystic Fibrosis Foundation Therapeutics, Gilead Sciences, Novartis, Taisho

and the Wellcome Trust.

References

1. Zhang Y, et al. Mortality attributable to carbapenem-resistant

Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg

Microbes Infect. 2016. Available here:

http://www.nature.com/emi/journal/v5/n3/full/emi201622a.html (accessed 20

April 2017).

2. Micek ST, et al. An international multicenter retrospective study of

Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.

Crit Care. 2015;19:219.

3. Armaganidis A, et al. Pharmacokinetic and efficacy analysis of

Murepavadin (POL7080) co-administered with standard-of-care (SOC) in a Phase

II study in patients with ventilator associated pneumonia (VAP) due to

suspected or documented Pseudomonas aeruginosa infection. Poster 1308,

ECCMID 2017.

4. Machacek M, et al. Population pharmacokinetics modeling of Murepavadin

(POL7080) and simulation of target attainment in a population with

ventilator-associated pneumonia due to infection with Pseudomonas aeruginosa.

Poster 1307, ECCMID 2017.

Zusatzmaterial zur Meldung:

Dokument: http://n.eqs.com/c/fncls.ssp?u=WOFLOLNQQF

Dokumenttitel: Polyphor_ECCMID_OMPTA

Ende der Medienmitteilung

566717 24.04.2017

°

@ dpa.de